{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:26Z","timestamp":1790705786763,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["drupjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.drup.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T10:02:33Z","timestamp":1404554553000},"page":"37-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside"],"prefix":"10.1016","volume":"17","author":[{"given":"Seyedmojtaba","family":"Seyedmousavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J.G.","family":"Melchers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2014.06.001_bib0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/03007990903485056","article-title":"Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"26","author":"AbuTarif","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.drup.2014.06.001_bib0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"AFST-EUCAST","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drup.2014.06.001_bib0005","series-title":"EUCAST Definitions of Clinical Breakpoints and Epidemiological Cut-off Values","author":"AFST-EUCAST","year":"2013"},{"key":"10.1016\/j.drup.2014.06.001_bib0520","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/dkq450","article-title":"Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies","volume":"66","author":"Alanio","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0020","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1128\/AAC.00942-07","article-title":"Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification","volume":"52","author":"Alcazar-Fuoli","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.drup.2004.06.002","article-title":"Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance","volume":"7","author":"Andes","year":"2004","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2014.06.001_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0050","doi-asserted-by":"crossref","first-page":"e10080","DOI":"10.1371\/journal.pone.0010080","article-title":"Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence","volume":"5","author":"Arendrup","year":"2010","journal-title":"PLOS ONE"},{"key":"10.1016\/j.drup.2014.06.001_bib0040","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1111\/j.1469-0691.2012.03890.x","article-title":"EUCAST technical note on Aspergillus and amphotericin B itraconazole, and posaconazole","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drup.2014.06.001_bib0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/infdis\/jis442","article-title":"In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration","volume":"206","author":"Arendrup","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2014.01.001","article-title":"Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.","volume":"16","author":"Arendrup","year":"2013","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2014.06.001_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/EC.4.3.625-632.2005","article-title":"Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus","volume":"4","author":"Balajee","year":"2005","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.drup.2014.06.001_bib0525","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/13693780902717018","article-title":"Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma","volume":"48","author":"Bellete","year":"2010","journal-title":"Med. Mycol."},{"key":"10.1016\/j.drup.2014.06.001_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/dkp416","article-title":"Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients","volume":"65","author":"Bruggemann","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0065","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/jac\/dkq280","article-title":"Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers","volume":"65","author":"Bruggemann","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0530","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/jac\/dkq279","article-title":"Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009","volume":"65","author":"Bueid","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jac\/dks451","article-title":"High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates","volume":"68","author":"Buied","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jac\/dks451","article-title":"High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates","volume":"68","author":"Buied","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0080","doi-asserted-by":"crossref","first-page":"e50034","DOI":"10.1371\/journal.pone.0050034","article-title":"Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing","volume":"7","author":"Camps","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.drup.2014.06.001_bib0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.05088-11","article-title":"Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature","volume":"56","author":"Camps","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0090","doi-asserted-by":"crossref","first-page":"e1003633","DOI":"10.1371\/journal.ppat.1003633","article-title":"Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health","volume":"9","author":"Chowdhary","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drup.2014.06.001_bib0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/dkt397","article-title":"Azole-resistant Aspergillus fumigatus with the environmental TR46\/Y121F\/T289A mutation in India","volume":"69","author":"Chowdhary","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.drup.2014.06.001_bib0535","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/dkh507","article-title":"Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma","volume":"55","author":"Chen","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0100","series-title":"Reference Method for Broth Dilution Antifungal SusceptibilityTesting of Filamentous Fungi; Approved standard","author":"CLSI","year":"2008"},{"key":"10.1016\/j.drup.2014.06.001_bib0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.06.001_bib0540","series-title":"American Society for Microbiology. 53rd ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy)","first-page":"A-292","article-title":"Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) IV in patients (Pts) at risk for invasive fungal infection (IFI)","author":"Cornely","year":"2013"},{"key":"10.1016\/j.drup.2014.06.001_bib0110","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0115","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1128\/AAC.48.11.4405-4413.2004","article-title":"In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance","volume":"48","author":"da Silva Ferreira","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0545","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0120","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2217\/fmb.11.118","article-title":"Azole resistance in Aspergillus: a growing public health menace","volume":"6","author":"Denning","year":"2011","journal-title":"Future Microbiol."},{"key":"10.1016\/j.drup.2014.06.001_bib0125","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1128\/AAC.47.3.1120-1124.2003","article-title":"A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus","volume":"47","author":"Diaz-Guerra","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0130","series-title":"European Public Assessment Report (EPAR) for Noxafil","author":"EMA","year":"2012"},{"key":"10.1016\/j.drup.2014.06.001_bib0135","series-title":"European Public Assessment Report (EPAR) for Vfend","author":"EMA","year":"2012"},{"key":"10.1016\/j.drup.2014.06.001_bib0140","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.drup.2014.06.001_bib0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800051011","article-title":"Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs","volume":"45","author":"Finlay","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2014.06.001_bib0150","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkt075","article-title":"The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus","volume":"68","author":"Fraczek","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.drup.2014.06.001_bib0550","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1128\/JCM.02330-07","article-title":"Rapid detection of triazole antifungal resistance in Aspergillus fumigatus","volume":"46","author":"Garcia-Effron","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.drup.2014.06.001_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3114\/sim.2007.59.01","article-title":"The current status of species recognition and identification in Aspergillus","volume":"59","author":"Geiser","year":"2007","journal-title":"Stud. Mycol."},{"key":"10.1016\/j.drup.2014.06.001_bib0160","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ajcp\/60.6.861","article-title":"Pulmonary aspergillosis caused by Aspergillus fischeri var. spinosus: report of a case and value of serologic studies","volume":"60","author":"Gerber","year":"1973","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.drup.2014.06.001_bib0165","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.bmc.2004.03.034","article-title":"Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase \u2018A\u2019 with azole antifungals","volume":"12","author":"Gollapudy","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drup.2014.06.001_bib0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","article-title":"Clinical pharmacology of antifungal compounds","volume":"17","author":"Groll","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.drup.2014.06.001_bib0175","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3201\/eid0809.020073","article-title":"Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil","volume":"8","author":"Guarro","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0180","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0185","doi-asserted-by":"crossref","first-page":"20262","DOI":"10.2807\/ese.17.36.20262-en","article-title":"Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany","volume":"17","author":"Hamprecht","year":"2012","journal-title":"Euro Surveill."},{"key":"10.1016\/j.drup.2014.06.001_bib0190","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/mic.0.2007\/007641-0","article-title":"Aspergillus flavus: human pathogen, allergen and mycotoxin producer","volume":"153","author":"Hedayati","year":"2007","journal-title":"Microbiology"},{"key":"10.1016\/j.drup.2014.06.001_bib0195","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.06.001_bib0200","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13693780802545600","article-title":"Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery","volume":"47","author":"Hodiamont","year":"2009","journal-title":"Med. Mycol."},{"key":"10.1016\/j.drup.2014.06.001_bib0205","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0210","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1111\/1469-0691.12148","article-title":"EUCAST technical note on voriconazole and Aspergillus spp","volume":"19","author":"Hope","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drup.2014.06.001_bib0215","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0220","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0225","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1128\/JCM.42.2.925-928.2004","article-title":"Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis","volume":"42","author":"Jarv","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.drup.2014.06.001_bib0230","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jis372","article-title":"Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints","volume":"206","author":"Jeans","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0235","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/jac\/dkq041","article-title":"Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands","volume":"65","author":"Klaassen","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0250","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0240","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0245","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0255","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1128\/AAC.01544-10","article-title":"Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole","volume":"55","author":"Kuipers","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0260","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","author":"Latge","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drup.2014.06.001_bib0265","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1128\/AAC.00833-13","article-title":"Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0270","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/AAC.01279-12","article-title":"Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0275","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1128\/AAC.05477-11","article-title":"The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0280","series-title":"52nd ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy), San Francisco, CA","first-page":"1946","article-title":"Phase 1B study of the pharmacokinetics (PK) and safety of posaconazole (POS) IV in patients (Pts) at risk for invasive fungal infection (IFI)","author":"Maertens","year":"2012"},{"key":"10.1016\/j.drup.2014.06.001_bib0285","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1128\/AAC.00931-09","article-title":"Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0290","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1128\/AAC.00606-10","article-title":"Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.drup.2014.06.001_bib0565","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1128\/AAC.05959-11","article-title":"Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis","volume":"56","author":"Meletiadis","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0300","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/JCM.39.7.2431-2438.2001","article-title":"Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species","volume":"39","author":"Mellado","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.drup.2014.06.001_bib0555","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.48.7.2747-2750.2004","article-title":"Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs","volume":"48","author":"Mellado","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0305","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0295","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.riam.2012.09.002","article-title":"Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia","volume":"30","author":"Mellado","year":"2013","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.drup.2014.06.001_bib0310","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1592\/phco.28.5.614","article-title":"Current options in antifungal pharmacotherapy","volume":"28","author":"Mohr","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drup.2014.06.001_bib0315","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0320","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/AAC.47.5.1719-1726.2003","article-title":"Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole","volume":"47","author":"Nascimento","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0325","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diagmicrobio.2013.04.022","article-title":"Differential expression of ATP-binding cassette and\/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus","volume":"76","author":"Natesan","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0330","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0335","series-title":"Phylogeny and Subgeneric Taxonomy of Aspergillus","author":"Peterson","year":"2008"},{"key":"10.1016\/j.drup.2014.06.001_bib0345","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0340","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/JCM.02136-10","article-title":"Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles","volume":"49","author":"Pfaller","year":"2011","journal-title":"J. Clin. Microbiol."},{"issue":"1 (Suppl.)","key":"10.1016\/j.drup.2014.06.001_bib0350","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drup.2014.06.001_bib0355","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1128\/AAC.01017-12","article-title":"First reported case of azole-resistant Aspergillus fumigatus due to the TR\/L98H mutation in Germany","volume":"56","author":"Rath","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0360","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0365","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drup.2014.06.001_bib0370","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.06.001_bib0375","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0380","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3201\/eid1905.130075","article-title":"Azole-resistant Aspergillus fumigatus, Iran","volume":"19","author":"Seyedmousavi","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0385","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/AAC.02226-12","article-title":"Pharmacodynamics and dose\u2013response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0390","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1128\/AAC.00980-12","article-title":"In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0395","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14787210.2013.826989","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis","volume":"11","author":"Seyedmousavi","year":"2013","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.drup.2014.06.001_bib0400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/07391102.2004.10506984","article-title":"Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions","volume":"22","author":"Sheng","year":"2004","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"6","key":"10.1016\/j.drup.2014.06.001_bib0570","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dku023","article-title":"Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"69","author":"Siopi","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0405","first-page":"929","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev."},{"key":"10.1016\/j.drup.2014.06.001_bib0425","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.drup.2014.06.001_bib0415","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AEM.00231-09","article-title":"Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles","volume":"75","author":"Snelders","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.drup.2014.06.001_bib0420","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/AAC.01599-09","article-title":"Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling","volume":"54","author":"Snelders","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0410","doi-asserted-by":"crossref","first-page":"e31801","DOI":"10.1371\/journal.pone.0031801","article-title":"Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus","volume":"7","author":"Snelders","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.drup.2014.06.001_bib0430","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0435","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus\u2013host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.06.001_bib0445","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/597465","article-title":"Azole-resistant central nervous system aspergillosis","volume":"48","author":"van der Linden","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.drup.2014.06.001_bib0455","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3109\/13693786.2010.499916","article-title":"Aspergillus species intrinsically resistant to antifungal agents","volume":"49","author":"van der Linden","year":"2011","journal-title":"Med. Mycol."},{"key":"10.1016\/j.drup.2014.06.001_bib0450","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0440","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles","volume":"57","author":"van der Linden","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0460","series-title":"Azole and non-azole MIC distributions of wild type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands","author":"van Ingen","year":"2014"},{"key":"10.1016\/j.drup.2014.06.001_bib0465","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0140-6736(07)61055-1","article-title":"Aspergillosis and a misleading sensitivity result","volume":"370","author":"van Leer-Buter","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2014.06.001_bib0560","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","article-title":"Azole resistance in Aspergillus fumigatus: a growing public health concern","volume":"26","author":"Vermeulen","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0475","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMc061720","article-title":"Multiple-triazole-resistant aspergillosis","volume":"356","author":"Verweij","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.06.001_bib0470","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drup.2009.09.002","article-title":"Azole-resistance in Aspergillus: proposed nomenclature and breakpoints","volume":"12","author":"Verweij","year":"2009","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2014.06.001_bib0480","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0490","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0485","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2014.06.001_bib0495","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/AAC.00587-10","article-title":"Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51)","volume":"54","author":"Warrilow","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0500","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1128\/AAC.00316-10","article-title":"Expression purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B","volume":"54","author":"Warrilow","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0505","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJM200212263472618","article-title":"Multidrug resistance in Aspergillus fumigatus","volume":"347","author":"Warris","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.06.001_bib0510","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.48.2.568-574.2004","article-title":"Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding","volume":"48","author":"Xiao","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2014.06.001_bib0515","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764614000351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764614000351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T14:43:22Z","timestamp":1649601802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764614000351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1368764614000351"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2014.06.001","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}